Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04592991
Other study ID # 202004104
Secondary ID
Status Terminated
Phase Early Phase 1
First received
Last updated
Start date October 7, 2020
Est. completion date April 4, 2022

Study information

Verified date April 2022
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to look at whether an investigational imaging agent, 64Cu-DOTA-ECL1i, used during Positron Emission Tomography (PET)/ Computed Tomography (CT) scanning, can help to identify conditions that place patients at an increased risk for AAA rupture. The study is also looking more closely at cellular, molecular and inflammatory properties of the aortic wall. Having the ability to identify markers that predict AAA progression/expansion and risk for rupture could allow the physician to manage patients in a more individualized, personal way.


Description:

Abdominal aortic aneurysm (AAA) is a life-threatening degenerative vascular disease characterized by transmural aortic macrophage infiltration, elastin degradation, and reduction of smooth muscle cell content. AAAs occurs later in life and are especially prevalent in men over the age of 65. Patients typically remain asymptomatic until rupture, which is associated with high mortality. Currently, surgical repair is the only approach for AAA treatment, and there is no pharmacological intervention. Clinically, ultrasound and computed tomography measurement of aneurysm diameter represents the mainstay of management and the principal determinant of timing for elective surgical repair. However, this anatomy-based approach fails to provide useful information about the cellular and molecular processes associated with aneurysm expansion and rupture. Therefore, developing translatable molecular biomarkers, specifically expressed by aneurysms, is necessary to determine associated status and progression, capture the risk of rupture, and deliver personalized treatment.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date April 4, 2022
Est. primary completion date April 4, 2022
Accepts healthy volunteers No
Gender All
Age group 45 Years to 75 Years
Eligibility Non-Aneurysmal Patients, (Aim 2A, n=3) Inclusion Criteria: - Patients with aortoiliac occlusive disease causing lifestyle limiting claudication, rest pain, and/or tissue loss that requires aortofemoral bypass Exclusion Criteria: - Patients with aortoiliac occlusive disease, we will apply the same exclusion criteria as AAA patients. Abdominal Aortic Aneurysm (AAA) Patients, (Aim 2B, n=5) Inclusion Criteria: - We will recruit asymptomatic patients with known AAAs by ultrasound, Doppler, and CT (men = 5.5 cm, women = 5.0cm); - Both men and women, between the ages of 45 -75; - With or without active tobacco use; Exclusion Criteria: - Inability to receive and sign informed consent; - Has a history of hypersensitivity to contrast agent, Iopamidol (Isovue) - Patients with Stage = 4 chronic renal failure (calculated by modification of diet in renal disease eGFR equation [to minimize confounding imaging variables]); - Inability to tolerate 60 minutes in a supine position with arms down at sides, as necessary for PET/CT; - Severe claustrophobia; - Positive pregnancy test or lactating; - Has a history of hypersensitivity to 64Cu-DOTA-ECL1i or any of its excipients; - Any condition that, in the opinion of the Sponsor-Investigator or designee could increase risk to the participant, limit the participant's ability to tolerate the research procedures or interfere with collection of the data such as: Symptomatic/recently treated coronary disease, cancer requiring oncologic management, or autoimmune/inflammatory diseases (e.g., rheumatoid arthritis or multiple sclerosis) that are known to have increased associated expression of CCR2.

Study Design


Intervention

Diagnostic Test:
Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i
Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with non-aneurysmal, atherosclerotic aortoiliac occlusive disease (n=3) will be enrolled in Aim 2A and undergo Cu-64 DOTA-ECL1i PET/CT.
AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i
Patients from both genders, all ethnic groups, and between the ages of 45 and 75 will be considered for recruitment. We will recruit patients who have evidence of abdominal aortic aneurysm (AAA) as our study patient cohort. Patients with Abdominal aortic aneurysm (AAA) (n=5) will be enrolled in Aim 2B and undergo Cu-64 DOTA-ECL1i PET/CT and contrast-enhanced CT angiography between 7-14 days of their scheduled elective open repair surgery.

Locations

Country Name City State
United States Washington University School of Medicine Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
Washington University School of Medicine

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary First in-person CCR2 molecular imaging using 64Cu-DOTA-ECL1i PET/CT in AAA patient Determine the background retention of 64Cu-DOTA-ECL1i in the abdominal aorta of patients with non-aneurysmal, atherosclerotic occlusive disease. 1-2 weeks
Primary Perform 64Cu-DOTA-ECL1i PET/CT in AAA patients and correlate imaging readouts with tissue inflammatory biomarkers in patients undergoing open repair Patients undergoing open AAA repair will be scheduled for PET/CT imaging at 1-2 weeks prior to surgery. This will be first-in-patient molecular imaging using CCR2 targeted 64Cu-DOTA-ECL1i in AAA patients undergoing open repair. The surgically removed aneurysmal tissue will be collected and processed for a complete characterization. 1-2 weeks prior to surgery
See also
  Status Clinical Trial Phase
Completed NCT01480206 - Overlay of 3D Scans on Live Fluoroscopy for Endovascular Procedures in the Hybrid OR
Active, not recruiting NCT03743142 - Assessment of the GORE® EXCLUDER® Conformable AAA Endoprosthesis In the Treatment of Abdominal Aortic Aneurysms
Active, not recruiting NCT02009644 - Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms N/A
Completed NCT01990950 - Fenestrated AAA Endovascular Graft Post-Approval Study N/A
Withdrawn NCT04551183 - Comparative Study of a Software With the Gold Standard N/A
Completed NCT02306304 - Ultra-sound for AAA Screening in Smoking Israeli Arab Men N/A
Recruiting NCT02295137 - Image Fusion of Preprocedural CTA With Real Time Fluoroscopy to Enhance EVAR Repair Phase 1
Recruiting NCT04586452 - NIH CCR2 AAA Study Early Phase 1
Completed NCT01726257 - Safety and Effectiveness Study of Endovascular Abdominal Aortic Aneurysm Repair Using the Nellix® System N/A
Terminated NCT02007252 - ACZ885 for the Treatment of Abdominal Aortic Aneurysm Phase 2
Completed NCT02934087 - Endovascular Aneurysm Repair (EVAR) Gate Study N/A
Terminated NCT03231397 - Predictors of AAA Expansion and/or Rupture Phase 4
Completed NCT04333641 - Development of Novel Imaging Markers Predicting the Progression of Abdominal Aortic Aneurysm Using 3D Computed Tomography